AOD-9604

Summary

AOD-9604 ("anti-obesity drug 9604") is a small synthetic piece of human growth hormone — specifically the tail end of the molecule (amino acids 176–191) with a tyrosine added — built on an appealing idea: capture growth hormone's fat-burning action while leaving out its growth-promoting and blood-sugar effects. It was developed as an oral obesity drug by an Australian company, and an early human study looked promising. But the story did not end well for the drug: its larger, pivotal program failed to establish meaningful weight loss, and development was discontinued. It was never FDA-approved. Today AOD-9604 is sold and hyped as a "fat-loss peptide" (and, more recently, a joint/cartilage-repair peptide), but that marketing rests on the early signal and on preclinical work — not on convincing human evidence, which is why the honest grade for its headline weight-loss claim is low.

What people use it for

AOD-9604 is marketed and used mainly for fat loss and body recomposition, on the premise that it mimics growth hormone's lipolytic ("fat-splitting") effect without raising IGF-1 or affecting blood sugar — making it sound like a "clean" fat-loss tool. A second, newer wave of marketing promotes it for joint, cartilage, and connective-tissue repair, often bundled with BPC-157 and TB-500 in "healing stacks." The evidence sections below weigh these uses against what the trials and preclinical work actually showed.

Human evidence

This is the crux, because AOD-9604's reputation runs well ahead of its human results.

The early positive signal. An early Phase 2, randomized, double-blind, placebo-controlled study in obese adults (Herd, Wittert, et al.) reported that a low (1 mg) daily oral dose produced statistically significant weight loss over 12 weeks compared with placebo — roughly a few kilograms versus under a kilogram — with improvements in glucose tolerance and a clean safety read. This is the result that launched AOD-9604's reputation, and on its own it looked encouraging.

The pivotal program that didn't replicate. The problem is what came next: the larger, longer pivotal Phase 2b program did not establish significant weight loss versus placebo at the doses tested, and the company discontinued development of AOD-9604 as an obesity drug. A positive small trial that fails to replicate in a larger, more definitive trial is a classic pattern — and in evidence terms, the larger negative result is the more reliable one. So despite the marketing, there is no convincing human evidence that AOD-9604 causes meaningful weight or fat loss, and it never earned drug approval. Evidence for the newer cartilage/joint-repair claims in humans is essentially absent.

Animal / preclinical evidence

The mechanism is where AOD-9604's appeal comes from, and it is genuinely interesting at the preclinical level. The molecule was derived from the fat-reducing C-terminal region of growth hormone, and in obese mice, chronic treatment with this modified fragment increased fat oxidation and reduced body weight, reproducing growth hormone's lipolytic effect without the growth-promoting or insulin-resistance effects that come from the rest of the hormone (Ng et al.). In cell and animal models it appears to stimulate lipolysis and inhibit lipogenesis. This is a plausible, well-described mechanism — which is exactly why the drug was worth testing in humans. But preclinical fat loss in mice plus a positive small human trial that failed to replicate is not the same as a proven human fat-loss drug, and the gap between the mechanism and the clinical results is the whole story here.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

Online, AOD-9604 users report modest fat loss (often around the abdomen), better body composition when combined with diet and training, and — in the newer "healing stack" framing — improved joint comfort and recovery. Reports generally describe a mild, subtle effect rather than a dramatic one, and they are confounded by the diet and exercise people undertake alongside it. Because the controlled human evidence for fat loss is unconvincing and the product is almost always gray-market, these reports carry low weight, and the usual unregulated-product quality concerns apply.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

The clearest published human dosing comes from the early obesity study, which used 1 mg once daily by mouth (an oral tablet formulation) for 12 weeks. Note two things this figure does not tell you: it is the dose from the small study whose result the larger program failed to replicate, and it was an oral formulation — different from the injectable "AOD-9604" sold in the gray market today. These numbers describe what was administered in a specific study; they are not a protocol to self-administer, and they do not transfer to research-only product of unknown content and route.

Safety & side effects

In the human studies that were done, AOD-9604 was relatively well tolerated, with no significant elevation of IGF-1 and no clear adverse effect on blood glucose — a key part of its "growth-hormone benefits without the downsides" pitch, and a real (if limited) finding. That said, "well tolerated in short studies" is not the same as "proven safe," and the safety database is small and short-term. The FDA, reviewing AOD-9604 among peptides nominated for compounding, specifically flagged concerns including the potential for immunogenicity (immune reactions to a peptide drug) and insufficient safety data to support its use — which is part of why it was not cleared for compounding. On top of that, the product sold online is unapproved, gray-market material of unverified identity, purity, and dose, which introduces the usual contamination and mislabeling risks independent of the molecule itself.

Regulatory / legal status

AOD-9604 is not an FDA-approved drug. It was developed as an oral obesity treatment, and after the larger pivotal studies did not establish significant weight loss, drug development was discontinued. Since then it has been marketed in some channels as a food-ingredient or cosmetic ingredient — but that is not drug approval and provides no support for weight-loss or therapeutic claims.

On the compounding side, the FDA evaluated AOD-9604 among nominated peptide substances and cited safety concerns (including immunogenicity risk and insufficient data); it was placed on the interim 503A "Category 2" list of bulk substances in 2023 and later removed in 2024 after the nomination was withdrawn — neither step constitutes approval, and the practical effect is that it is not a sanctioned compounding ingredient. What remains is a large gray market selling AOD-9604 as a "research only" fat-loss peptide, which is unapproved and unregulated. Status varies by country and can change; this is not legal or medical advice.

Podcast / media mentions

AOD-9604 is a fixture of fat-loss and "peptide stack" content, usually framed as a growth-hormone fragment that "burns fat without the side effects." The accurate core: the mechanism is real and elegant — it was deliberately engineered from growth hormone's fat-reducing region — and in mice and one small human study it did what it was designed to do. The misleading leap is treating that as proof it works as a fat-loss drug in people: the pivotal human program failed, the drug was abandoned, and it never got approved — facts that rarely make it into the promotional version. The more recent repositioning as a cartilage/joint-repair peptide has even less human support. Where coverage presents AOD-9604 as an interesting but unproven fragment whose development stalled, it squares with the record; where it implies a validated, side-effect-free fat-loss solution, it runs well ahead of the evidence. The critique is of the framing, not of the underlying science.